Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Design and Characterization of Nanoemulsion for Transdermal Delivery of Meloxicam

Design and Characterization of Nanoemulsion for Transdermal Delivery of Meloxicam AbstractMeloxicam is used to treat pain or inflammation in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases. The main objective of this study is to develop a potential of nanoemulsion for transdermal delivery of meloxicam for the treatment of rheumatoid arthritis. Solubility of the meloxicam was determined in different oils, surfactants and cosurfactants. Of the oil tested, labrafil 1944 CS was chosen as oil phase of nanoemulsion, as it showed a good solubilizing capacity and excellent drug penetration. The nanoemulsion area was identified by constructing pseudo ternary phase diagram. The prepared nanoemulsion was subjected to different thermodynamic test. The nanoemulsion formulation was characterized for viscosity, particle size and polydispersity index (PCS), transmission electron microscopy (TEM), refractive index, in vitro permeation study and stability study. Drug content of all the formulations was found to be between 98.7±0.004% to 102.42±0.002%. The mean droplet size of C2 formulation was found to be small (60.6 nm) as compared to other formulation, polydispersity index 0.22, zeta potential 0.86 mv. The C2 formulation showed highest flux (29.69 μgcm-2h-1) as compared to other formulation. After stability study no significant change was observed in viscosity, drug content and pH. The result proposed that prepared nanoemulsion could be promising to improving transdermal efficacy of meloxicam in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Analytical Chemistry Letters Taylor & Francis

Design and Characterization of Nanoemulsion for Transdermal Delivery of Meloxicam

Download PDF

Design and Characterization of Nanoemulsion for Transdermal Delivery of Meloxicam

Abstract

AbstractMeloxicam is used to treat pain or inflammation in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases. The main objective of this study is to develop a potential of nanoemulsion for transdermal delivery of meloxicam for the treatment of rheumatoid arthritis. Solubility of the meloxicam was determined in different oils, surfactants and cosurfactants. Of the oil tested, labrafil 1944 CS was chosen as oil phase of nanoemulsion, as it showed a good solubilizing...
Loading next page...
 
/lp/taylor-francis/design-and-characterization-of-nanoemulsion-for-transdermal-delivery-aUb64wx62q
Publisher
Taylor & Francis
Copyright
© 2016 Har Krishan Bhalla & Sons
ISSN
2230-7532
eISSN
2229-7928
DOI
10.1080/22297928.2016.1209126
Publisher site
See Article on Publisher Site

Abstract

AbstractMeloxicam is used to treat pain or inflammation in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases. The main objective of this study is to develop a potential of nanoemulsion for transdermal delivery of meloxicam for the treatment of rheumatoid arthritis. Solubility of the meloxicam was determined in different oils, surfactants and cosurfactants. Of the oil tested, labrafil 1944 CS was chosen as oil phase of nanoemulsion, as it showed a good solubilizing capacity and excellent drug penetration. The nanoemulsion area was identified by constructing pseudo ternary phase diagram. The prepared nanoemulsion was subjected to different thermodynamic test. The nanoemulsion formulation was characterized for viscosity, particle size and polydispersity index (PCS), transmission electron microscopy (TEM), refractive index, in vitro permeation study and stability study. Drug content of all the formulations was found to be between 98.7±0.004% to 102.42±0.002%. The mean droplet size of C2 formulation was found to be small (60.6 nm) as compared to other formulation, polydispersity index 0.22, zeta potential 0.86 mv. The C2 formulation showed highest flux (29.69 μgcm-2h-1) as compared to other formulation. After stability study no significant change was observed in viscosity, drug content and pH. The result proposed that prepared nanoemulsion could be promising to improving transdermal efficacy of meloxicam in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases.

Journal

Analytical Chemistry Letters – Taylor & Francis

Published: May 3, 2016

Keywords: Meloxicam; non-steroidal anti-inflammatory drug; rheumatoid arthritis; nanoemulsion; transmission electron microscopy .

References

  • Clinical pharmacokinetics of meloxicam
  • Clinical pharmacokinetics of meloxicam
  • Local enhanced topical delivery (LETD) of drugs: does it truly exist?
  • The cost of unsafe injections
  • A review of ageing and an examination of clinical methods in the assessment of ageing skin. Part 2: clinical perspective s and clinical methods in evaluation of ageing skin
  • Nanoemulsions as vehicles for transdermal delivery of aceclofenac
  • Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol
  • Microemulsion-based novel transdermal delivery system of tetramethylpyrazine: preparation and evaluation in vitro and in vivo
  • Microemulsions
  • Microemulsion-based media as novel drug delivery system
  • Nanoemulsion system for transdermal delivery of tamoxifen citrate, design, characterization: Effect of penetration enhancer
  • Nanoemulsion components screening and selection: a technical note
  • Novel nanoemulsion as vehicles for transdermal delivery of clozapine: In vitro and in vivo studies
  • Formulation of microemulsion gel system for transdermal delivery of celecoxib: In vitro permeation, anti-inflammatory activity and skin irritation
  • A detailed review on nanoemulsion drug delivery system
  • Nanoemulsion as a novel transdermal drug delivery system
  • Cationic nanoemulsions as non-viral vectors for plasmid DNA delivery
  • A study on factors influencing, the droplet size in nonlionic oil in water microemulsions
  • Nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoidal carcinoma model compared to suspension
  • Nanoemulsion gel formulation of aceclofenac for topical delivery
  • Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs
  • Glibenclamide transdermal patches: Physicochemical, pharmacodynamic and pharmacokinetic evaluation
  • An investigation into mechanism of self emulsification using particle size analysis and low frequency dielectric spectroscopy
  • Microemulion-based media as novel drug delivery system
  • Studies on microemulsions using Brij-96 as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants
  • Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment